HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chi-Tai Yeh Selected Research

ovatodiolide

9/2019Ovatodiolide suppresses inflammatory response in BEAS-2B cells by regulating the CREB/AQP5 pathway, and sensitizes nasopharyngeal carcinoma cells to radiation therapy.
8/2019Ovatodiolide inhibits the oncogenicity and cancer stem cell-like phenotype of glioblastoma cells, as well as potentiate the anticancer effect of temozolomide.
7/2018Investigation of ovatodiolide, a macrocyclic diterpenoid, as a potential inhibitor of oral cancer stem-like cells properties via the inhibition of the JAK2/STAT3/JARID1B signal circuit.
1/2018Downregulation of Cancer Stemness by Novel Diterpenoid Ovatodiolide Inhibits Hepatic Cancer Stem Cell-Like Traits by Repressing Wnt/[Formula: see text]-Catenin Signaling.
8/2015Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Chi-Tai Yeh Research Topics

Disease

71Neoplasms (Cancer)
06/2022 - 03/2005
18Neoplasm Metastasis (Metastasis)
06/2022 - 05/2012
15Hepatocellular Carcinoma (Hepatoma)
06/2021 - 03/2005
12Carcinogenesis
09/2021 - 07/2012
12Breast Neoplasms (Breast Cancer)
01/2021 - 12/2007
8Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2022 - 01/2013
8Lung Neoplasms (Lung Cancer)
09/2019 - 12/2012
7Inflammation (Inflammations)
01/2022 - 11/2013
7Squamous Cell Carcinoma of Head and Neck
01/2022 - 11/2015
7Glioblastoma (Glioblastoma Multiforme)
09/2021 - 01/2015
5Glioma (Gliomas)
08/2021 - 01/2015
5Colorectal Neoplasms (Colorectal Cancer)
07/2021 - 05/2012
5Triple Negative Breast Neoplasms
01/2021 - 06/2015
5Mouth Neoplasms (Oral Cancer)
07/2018 - 01/2013
5Body Weight (Weight, Body)
11/2009 - 06/2004
3Disease Progression
09/2021 - 02/2016
3Hypoxia (Hypoxemia)
08/2021 - 01/2017
3Colonic Neoplasms (Colon Cancer)
01/2021 - 11/2009
3Ovarian Neoplasms (Ovarian Cancer)
05/2017 - 05/2015
2Osteoarthritis
06/2022 - 10/2021
2Pancreatic Neoplasms (Pancreatic Cancer)
06/2022 - 10/2018
2Coronary Vasospasm (Coronary Artery Vasospasm)
01/2022 - 01/2018
2Prostatic Neoplasms (Prostate Cancer)
09/2021 - 01/2021
2Liver Neoplasms (Liver Cancer)
06/2021 - 01/2018
2Myocardial Infarction
03/2021 - 01/2020
2Wounds and Injuries (Trauma)
01/2021 - 01/2020
2Adenocarcinoma
01/2020 - 10/2005
2Syndrome (Syndromes)
09/2019 - 07/2019
2Adenocarcinoma of Lung
01/2018 - 01/2013
1Coronary Artery Disease (Coronary Atherosclerosis)
06/2022

Drug/Important Bio-Agent (IBA)

18CateninsIBA
01/2021 - 01/2011
12Proteins (Proteins, Gene)FDA Link
08/2021 - 03/2011
10Cisplatin (Platino)FDA LinkGeneric
06/2022 - 01/2013
8Pharmaceutical PreparationsIBA
06/2022 - 12/2007
7Biomarkers (Surrogate Marker)IBA
06/2022 - 01/2018
7MicroRNAs (MicroRNA)IBA
01/2021 - 07/2013
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
08/2021 - 01/2017
5ovatodiolideIBA
09/2019 - 08/2015
5pterostilbeneIBA
06/2015 - 01/2013
4Messenger RNA (mRNA)IBA
06/2022 - 01/2012
4p38 Mitogen-Activated Protein KinasesIBA
01/2022 - 05/2006
4ErbB Receptors (EGF Receptor)IBA
11/2021 - 12/2013
4Tyrosine Kinase InhibitorsIBA
11/2021 - 01/2018
4Interleukin-6 (Interleukin 6)IBA
10/2021 - 01/2018
4Temozolomide (Temodar)FDA LinkGeneric
09/2021 - 01/2015
4Agammaglobulinaemia Tyrosine KinaseIBA
07/2021 - 05/2015
4garcinolIBA
03/2021 - 01/2018
44-acetylantroquinonol BIBA
01/2021 - 10/2015
4Biological ProductsIBA
01/2021 - 01/2006
4Caspase 3 (Caspase-3)IBA
01/2020 - 05/2012
4honokiolIBA
01/2017 - 01/2013
3AntioxidantsIBA
01/2022 - 06/2005
3Cadherins (E-Cadherin)IBA
01/2022 - 08/2019
3acalabrutinibIBA
08/2021 - 12/2020
3EnzymesIBA
01/2021 - 06/2005
3DiterpenesIBA
08/2019 - 01/2018
3Histone DemethylasesIBA
01/2018 - 01/2015
3destruxin BIBA
06/2014 - 05/2012
3cyanidinIBA
03/2012 - 03/2005
3Gallic AcidIBA
03/2009 - 01/2006
3p-coumaric acidIBA
03/2009 - 01/2006
3AcidsIBA
05/2006 - 06/2005
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
06/2022 - 07/2019
2PlatinumIBA
01/2022 - 01/2013
2Lipoprotein(a)IBA
01/2022 - 03/2021
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
11/2021 - 07/2021
2osimertinibIBA
11/2021 - 07/2021
2Therapeutic UsesIBA
10/2021 - 11/2015
2Sorafenib (BAY 43-9006)FDA Link
06/2021 - 06/2021
2Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA
03/2021 - 01/2018
2VimentinIBA
01/2021 - 08/2019
2Long Noncoding RNAIBA
01/2021 - 02/2016
2ibrutinibIBA
12/2020 - 05/2015
2PD 173074IBA
01/2020 - 10/2018
2Polysaccharides (Glycans)IBA
09/2019 - 07/2019
2Interleukin-10 (Interleukin 10)IBA
09/2019 - 07/2019
2Antineoplastic Agents (Antineoplastics)IBA
08/2019 - 08/2015
2Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA
10/2018 - 07/2012
2Imatinib Mesylate (Gleevec)FDA Link
01/2018 - 07/2012
2matrigelIBA
01/2017 - 06/2015
2antrocinIBA
12/2013 - 02/2011
2sulforaphaneIBA
07/2012 - 12/2005
2TriterpenesIBA
09/2010 - 11/2009
2JNK Mitogen-Activated Protein KinasesIBA
09/2010 - 03/2005
2caffeic acidIBA
11/2009 - 06/2004
2hsian-tsaoIBA
11/2009 - 06/2004
2ferulic acid (sodium ferulate)IBA
03/2009 - 01/2006
22,5-dihydroxybenzoic acid (gentisic acid)IBA
08/2006 - 01/2006
2malvidinIBA
10/2005 - 03/2005
2delphinidinIBA
10/2005 - 03/2005
2Anthocyanins (Anthocyanin)IBA
10/2005 - 03/2005
1Small Interfering RNA (siRNA)IBA
06/2022
1human MIRN497 microRNAIBA
06/2022
1fatostatinIBA
06/2022
1Growth Differentiation Factor 15IBA
06/2022
1Mitogen-Activated Protein Kinase 14IBA
06/2022

Therapy/Procedure

22Therapeutics
06/2022 - 01/2012
9Drug Therapy (Chemotherapy)
01/2022 - 01/2012
6Radiotherapy
01/2020 - 01/2012
2Aftercare (After-Treatment)
07/2018 - 01/2015